pioneer plus semaglutide Oral versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial PIONEER 6: Oral Semaglutide Passes

Interleukin-1 (IL-1) receptor antagonist gene polymorphism in normal weight obese syndrome: relationship to body composition and IL-1 alpha and beta plasma levels

This could happen if the treatment and control groups are not comparable- for example if doctors prescribed GLP-1s vs another diabetes medication for systematic reasons such as the health profile of the patient

Besides, GLP-1RA NLY01 could significantly reduce the proportion of infiltrating white blood cells (CD45 high ) and monocytes (Clec12a + ) in the central nervous system (CNS), while decreasing the number of effector/memory T cells (CD4 + CD44 + ) and inhibiting inflammation in peripheral circulation and CNS (90)

V.KoftinaV

doi: 10.1002/cncr.33819 26 ShawCMortimerPJuddPA